Cargando…

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody

CD40-targeting therapies can enhance the dendritic cell priming of tumor-specific T cells and repolarize intratumoral macrophages to alleviate the tumoral immunosuppressive environment and remodel the extracellular matrix. Mitazalimab is a potent agonistic CD40 monoclonal IgG1 antibody currently und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersson, Hampus, Sobti, Aastha, Jimenez, David Gomez, de Coaña, Yago Pico, Ambarkhane, Sumeet Vijay, Hägerbrand, Karin, Smith, Karin Enell, Lindstedt, Malin, Ellmark, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572020/ https://www.ncbi.nlm.nih.gov/pubmed/37830579 http://dx.doi.org/10.3390/cells12192365

Ejemplares similares

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
por: Deronic, Adnan, et al.
Publicado: (2021)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer
por: Sobti, Aastha, et al.
Publicado: (2023)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Immune Phenotypes of Nasopharyngeal Cancer
por: Nilsson, Johan S., et al.
Publicado: (2020)

Targeted spatial proteomic analysis of CD8(+) T- and myeloid cells in tonsillar cancer
por: Altunbulakli, Can, et al.
Publicado: (2023)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
por: Babačić, Haris, et al.
Publicado: (2020)

Single-cell analysis of myeloid cells in HPV(+) tonsillar cancer
por: Jimenez, David Gomez, et al.
Publicado: (2023)

Transcriptional profiling demonstrates altered characteristics of CD8 (+) cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemia
por: Abolhalaj, Milad, et al.
Publicado: (2022)

Tonsillar Cancer with High CD8(+) T-Cell Infiltration Features Increased Levels of Dendritic Cells and Transcriptional Regulation Associated with an Inflamed Tumor Microenvironment
por: Jimenez, David Gomez, et al.
Publicado: (2021)

Counteracting CAR T cell dysfunction
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma
por: Melief, Jeroen, et al.
Publicado: (2020)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production
por: Gentilcore, Giusy, et al.
Publicado: (2014)

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
por: Pico de Coaña, Yago, et al.
Publicado: (2015)

Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
por: Pico de Coaña, Yago, et al.
Publicado: (2014)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015)

Synergistic effects of agonistic costimulatory antibodies adsorbed to amphiphilic poly(γ-glutamic acid) nanoparticles
por: Freiburghaus, Catja, et al.
Publicado: (2013)

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
por: Pico de Coaña, Yago, et al.
Publicado: (2020)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
por: Rad Pour, Soudabeh, et al.
Publicado: (2021)

Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma
por: Ligtenberg, Maarten A., et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
por: Selvin, Tove, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti‐CD40 monoclonal antibody, in kidney transplantation
por: Vincenti, Flavio, et al.
Publicado: (2019)

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
por: de Coaña, Yago Pico, et al.
Publicado: (2017)

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison
por: Cordoba, Raul, et al.
Publicado: (2022)

Laboratory-Based Factors Predicting Skiing Performance in Female and Male Biathletes
por: Laaksonen, Marko S., et al.
Publicado: (2020)

Potent neutralizing monoclonal antibodies against Ebola virus infection
por: Zhang, Qi, et al.
Publicado: (2016)

Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer
por: Nilsson, Johan S., et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942
por: Burgess, Gary, et al.
Publicado: (2018)

Coagulative safety of epidural catheters after major upper gastrointestinal surgery: advanced and routine coagulation analysis in 38 patients
por: Thomas, Owain, et al.
Publicado: (2016)

Population pharmacokinetics and pharmacodynamics of dobutamine in neonates on the first days of life
por: Hallik, Maarja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_erhalg95id727kbsluvea6h7so